Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study

Shamshiri, H. and Fatehi, F. and Davoudi, F. and Mir, E. and Pourmirza, B. and Abolfazli, R. and Etemadifar, M. and Harirchian, M.H. and Gharagozli, K. and Ayromlou, H. and Basiri, K. and Zamani, B. and Rohani, M. and Sedighi, B. and Roudbari, A. and Delavar Kasmaei, H. and Nikkhah, K. and Ranjbar Naeini, A. and Nafissi, S. (2015) Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 16 (7-8). pp. 506-511.

Full text not available from this repository.
Official URL:


This study was designed to evaluate ALS progression among different subgroups of Iranian patients.Three hundred and fifty-eight patients from centres around the country were registered and their progression rate was evaluated using several scores including Manual Muscle Test scoring (MMT) and the revised ALS Functional Rating Scale (ALSFRS-R). Progression rate was analysed separately in subgroups regarding gender, onset site, stage of disease and riluzole consumption. A significant difference in MMT deterioration rate (p = 0.01) was noted between those who used riluzole and those who did not. No significant difference was observed in progression rates between male/female and bulbar-onset/limb-onset groups using riluzole. In conclusion, riluzole has a significant effect on muscle force deterioration rate but not functional scale. Progression rate was not influenced by site of onset or gender. © 2015 Taylor & Francis.

Item Type: Article
Additional Information: cited By 3
Depositing User: eprints admin
Date Deposited: 02 Jul 2018 08:42
Last Modified: 02 Jul 2018 08:42

Actions (login required)

View Item View Item